Journal: Nature Aging
Article Title: Reduced ULK1 links impaired autophagy and mitophagy to Alzheimer’s disease pathology
doi: 10.1038/s43587-026-01108-z
Figure Lengend Snippet: a , Serum ULK1 (pg ml −1 ) was quantified in CU study participants at baseline ( n = 21) and 4 years later ( n = 21). n = number of study participants per experimental group. b , CSF ULK1 (pg ml −1 ) was quantified in CU controls at baseline ( n = 22) and 4 years later ( n = 22). c , Changes of hippocampal ULK1 in different age groups. Post-mortem hippocampal samples from young, middle-aged and old people ( n = 8 per group). Original WB data are provided in Extended Data Fig. . d , Tissue sections (7 µm) were prepared from HIP of human post-mortem brain tissues from middle-aged and old groups. Slides were stained for ULK1 (green), MAP2 (red) and DAPI (blue). Scale bars, 20 μm. e , f , Quantification of immunofluorescent signals in tissues ( d ) in two ways, including with the data presented as ULK1-positive (ULK1 + ) neurons/total neurons ( e ) or signal intensity per neuron ( f ) ( n = 4 and 6). g , Bar chart comparing serum ULK1 (ln transformed pg ml −1 ) in CU, AD-MCI and AD-dementia patients. Data points were subjected to ln transformation to correct for skewed data distribution. n = number of participants per group. (Age, years ± s.d., min–max: CU, 71.8 ± 6.4, 64–89 years; AD-MCI, 70.6 ± 5.4, 52–81 years; AD-dementia, 69.7 ± 6.7, 49–84 years.) h , Box plots showing changes of CSF ULK1 in designated groups. (Age, years ± s.d., min–max: CU, 72.2 ± 6.4, 64–89 years; AD-MCI, 70.7 ± 5.9, 49–81 years; AD-dementia, 70.2 ± 6.4, 49–84 years.) i , Heat map for relative abundance of ULK1 small nuclear RNA (snRNA) stratified by Braak stages (0–2, 3–4, 5–6) and brain cell types. Data represent single-nucleus RNA samples prepared from post-mortem human brain. j , k , Changes of neuronal ULK1 expression between old control and AD hippocampal tissues. ULK1 (green), MAP2 (red) and DAPI (blue). A representative set of images ( j ) and quantified data in the form of ULK1-positive (ULK1 + ) neurons/total neurons ( k ) ( n = 6 and 7). Scale bars, 20 μm ( j ). l , CDR-SB data showing that higher ULK1 correlates with slower AD progression. CSF ULK1 was measured at baseline and the patient cohort stratified into subgroups with low (50 pg ml −1 ), medium (150 pg ml −1 ) or high (250 pg ml −1 ) expression of ULK1. CDR-SB protocol was administered at 1-, 3- or 5-year follow-up assessment. The graph shows linear regression for CDR-SB score versus time. Unless specified elsewhere, data are mean ± s.e.m. Statistical analyses used were as follows: paired t -test ( a , b ), two-sided unpaired two-tailed Student’s t -test ( e , f , k ). One-way ANOVA followed by Dunnett’s multiple comparisons test ( c ) and by Tukey’s multiple comparisons test ( g, h ) and Wilcoxon test ( i ). Oli., oligodendrocytes; Ex., excitatory neurons; In., inhibitory neurons; Ast., astrocytes; Opc., oligodendrocyte progenitor cells; Mic., microglia; CI, confidence interval. * P < 0.05, ** P < 0.01, *** P < 0.001.
Article Snippet: The siRNA reagents used including siRNA targeting ULK1 (catalog no. SR322391, OriGene), PINK1 (catalog no. SR324912, OriGene), Parkin (catalog no. SR321228, OriGene), FUNDC1 (catalog no. SR315322, OriGene), Ambra1 (catalog no. SR310808, OriGene), BNIP3 (catalog no. SR300461, OriGene), BNIP3L/NIX (catalog no. SR300462, OriGene), GSK3-beta (catalog no. SR301979, OriGene), ULK2 (catalog no. SC-44183, Santa Cruz Biotechnology), Atg5 (catalog no. SR322789, OriGene), Beclin1 (catalog no. SR322490, OriGene), Sirt1 (catalog no. SR323581, OriGene) or scramble control siRNA Oligo Duplexes at 100 nM.
Techniques: Staining, Transformation Assay, Expressing, Control, Two Tailed Test